MedTrace Logo

In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity

NCT04368897 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2023-07-19

No results posted yet for this study

Summary

The COVID-19 Androgen Sensitivity Test is a non-invasive In-Vitro Diagnostic device that utilizes Next Generation Sequencing Technology (NGS). The results of the test are used by a physician to assess the risk of developing severe symptoms following COVID-19 infection, The COVID-19 Androgen Sensitivity Test requires a health care professional to collect a DNA sample using an FDA cleared DNA sample collection kit.

Conditions

Interventions

DIAGNOSTIC_TEST

CAG length <22

CAG repeat length in exon 1 of AR gene

DIAGNOSTIC_TEST

CAG length >=22

CAG repeat length in exon 1 of AR gene

Sponsors & Collaborators

  • Hospital Universitario Ramon y Cajal

    collaborator OTHER

  • Applied Biology, Inc.

    lead INDUSTRY

Principal Investigators

  • Sabina Herrera, MD · Hospital Universitario Ramon y Cajal

  • Carlos Wambier, MD · Brown University

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2022-12-01
Completion
2022-12-01

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04368897 on ClinicalTrials.gov